Abstract Library

#3017 Patient and Healthcare Practitioner Perspectives of Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review

Introduction: Somatostatin analogs (SSAs) are used to treat acromegaly and neuroendocrine tumors (NETs). Two first-generation SSAs, octreotide and lanreotide, are available to patients (pts).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cella D

Authors: Feuilly M, Jenni E, Cella D,

Keywords: neuroendocrine tumors, acromegaly, preference, patient reported outcomes,

#2163 Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Carcinomas: Case Series

Introduction: High-grade neuroendocrine carcinomas (NECs) possess inevitable tendencies to metastasise and hold poor prospects of survival. Patients with neuroendocrine tumours who progress after medical management can be treated with peptide receptor radionuclide therapy (PRRT), on the proviso that there is positive uptake on 68Ga-DOTATATE PET/CT imaging. Despite this, a proportion of patients who exhibit positive imaging respond poorly to therapy. Management of NECs is currently limited; evidence for treating NECs with PRRT is scarce.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Butt S, Evans J, Sharma R,

Keywords: neuroendocrine, carcinoma, tumours, PRRT,

#2118 Reassessment of Risk Factors Associated with Locoregional Lymph Nodal Metastases in Well-Differentiated Appendiceal Neuroendocrine Neoplasms

Introduction: To prevent loco-regional recurrence and subsequent development of distant metastases in Appendiceal Neuro-Endocrine Neoplasms (ANEN), the existing Guidelines have identified risk factors which would indicate a prophylactic right hemicolectomy(RHC).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Galanopoulos M, Evans N, McFadyen R, Naik R, Drami I,

Keywords: appendix, neuroendocrine neoplasm, lymph node metastases, appendicectomy, right hemicolectomy,

#741 Lanreotide Activity and Synergy in Combination with Targeted Agents in Gastrointestinal Neuroendocrine Tumors (GI-NET): Ex Vivo Analysis of Programmed Cell Death (EVA/PCD) in GI-NETs Isolated from Patients with Advanced Disease

Introduction: Somatostatin receptor ligation can affect vascular signals, induce apoptosis and provide objective responses in some GI-NET patients.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Nagourney R, Evans S, Woltering E, Gomez-Panzani E,

Keywords: combination therapy,